/ Published in 2019, Publication

Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen with Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines

Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen with Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data from a Phase 1 Randomized Clinical Trial in Uganda and Tanzania.

Anywaine Z, Whitworth H, Kaleebu P, Praygod G, Shukarev G, Manno D, Kapiga S, Grosskurth H, Kalluvya S, Bockstal V, Anumendem D, Luhn K, Robinson C, Douoguih M, Watson-Jones D.

J Infect Dis 2019; 220:46-56.

PMID:30796818

PMCID:PMC6548900

DOI:10.1093/infdis/jiz070

Related citation

What you can read next

Sustained high blood pressure and 24-h ambulatory blood pressure monitoring in Tanzanian adolescents.
Implementing good participatory practice guidelines in the FEM-PrEP preexposure prophylaxis trial for HIV prevention among African women
Microbicides Development Programme. Are women who work in bars, guesthouses and similar facilities a suitable study population for vaginal microbicide trials in Africa?